Affimed N.V. (AFMD)

(AFMD) Investment Analysis - Stock Traders Daily

Stock Traders Daily

Affimed (NASDAQ:AFMD) Sees Significant Drop in Short Interest - MarketBeat

MarketBeat

Imagine Holding Affimed (NASDAQ:AFMD) Shares While The Price Zoomed 323% Higher - Yahoo Movies Canada

Yahoo Movies Canada

Affimed reports acceptance of abstract on AFM28 preclinical data at EHA 2024 - TipRanks.com - TipRanks

TipRanks

Affimed (NASDAQ:AFMD) Shares Cross Above 50-Day Moving Average of $5.34 - MarketBeat

MarketBeat

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European ... - GlobeNewswire

GlobeNewswire

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress

GlobeNewswire Inc.

Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research

Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq - Yahoo Lifestyle Australia

Yahoo Lifestyle Australia

Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq - Yahoo Movies UK

Yahoo Movies UK

Analyzing How You Should Play Cigna (CI) Ahead of Q1 Earnings

Zacks Investment Research

Bispecific and Trispecific Antibody Industry Key Trends |AbbVie, Affimed, Biotheus, Biontech - Motions Online

Motions Online

Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade

Zacks Investment Research

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology

GlobeNewswire Inc.

Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade - Yahoo Finance

Yahoo Finance

Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Zacks Investment Research

Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?

Zacks Investment Research

Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

Affimed Reports 2023 Financial Results and Operational Progress

GlobeNewswire Inc.

Affimed Reports 2023 Financial Results and Operational Progress - GlobeNewswire

GlobeNewswire

Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024

GlobeNewswire Inc.

Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research

Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Yahoo Finance

Why Is Affimed (AFMD) Stock Moving Today? - InvestorPlace

InvestorPlace

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Affimed Announces 1-for-10 Reverse Stock Split

GlobeNewswire Inc.

Affimed Announces 1-for-10 Reverse Stock Split - GlobeNewswire

GlobeNewswire

Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

AFMD Stock Quote Price and Forecast - CNN

CNN

Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

GlobeNewswire Inc.

Affimed Announces Leadership Change and Organizational Restructuring - Yahoo Finance

Yahoo Finance

Why Resources Connection Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

Benzinga

Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck

GlobeNewswire Inc.

Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck - Yahoo Finance

Yahoo Finance

Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients

GlobeNewswire Inc.

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

GlobeNewswire Inc.

Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24

GlobeNewswire Inc.

Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround - Yahoo Finance

Yahoo Finance

Affimed (NASDAQ:AFMD) shareholders have endured a 78% loss from investing in the stock three years ago - Yahoo Finance

Yahoo Finance

New Affimed data disappoints after Nasdaq flags stock dip - Fierce Biotech

Fierce Biotech

Affimed begins subject dosing in acute myeloid leukaemia therapy trial - Clinical Trials Arena

Clinical Trials Arena

Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed ... - GlobeNewswire

GlobeNewswire

ASH 2022: Affimed ICEd in one trial but ROCKs another; lymphoma efforts Redirected - BioWorld Online

BioWorld Online

Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager ... - GlobeNewswire

GlobeNewswire

Affimed Stock: Preparing For Key Inflection Points (NASDAQ:AFMD) - Seeking Alpha

Seeking Alpha

Affimed Provides Update on ASCO AFM13-104 Oral Presentation - GlobeNewswire

GlobeNewswire

AACR Quick Takes: Affimed impresses with NK cell/bispecific antibody combination - BioCentury

BioCentury

AACR 2022: New 'killer' immunotherapy shows early promise in range of solid tumours - The Institute of Cancer Research

The Institute of Cancer Research